ERBB2 and neoplasm: Anti-HER2 ADCs share one main mechanism for targeting tumors where mABs function as transport systems carrying cytotoxic payloads to HER2 overexpressing tumor cells and binding to the extracellular domain of the HER2 protein [134,135,136].